Cardiac Contractility Modulation as bridge to recovery in a patient with advanced heart failure evaluated for left ventricular assist devices: a case report and review of literature
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Cardiac Contractility Modulation (CCM) therapy served as a bridge to recovery for a heart failure patient, eliminating the need for a left ventricular assist device (LVAD). This advanced heart failure treatment shows promise for improved patient outcomes.
Area Of Science
- Cardiology
- Biomedical Engineering
Background
- Advanced heart failure (HFrEF) often necessitates mechanical circulatory support like left ventricular assist devices (LVADs).
- Cardiac Contractility Modulation (CCM) is an emerging therapy for specific heart failure patient groups.
Observation
- A case report details a patient initially considered for LVAD implantation.
- The patient underwent CCM therapy, leading to significant clinical and functional improvements.
- Post-CCM, the patient stabilized in NYHA class II, experiencing no further acute heart failure episodes.
Findings
- CCM therapy successfully bridged the patient to recovery, negating the need for LVAD.
- The patient demonstrated sustained stability and improved functional capacity.
- The advanced heart failure designation was no longer applicable due to recovery.
Implications
- CCM presents a viable, less invasive alternative to LVAD for select advanced HFrEF patients.
- Favorable aspects include ease of implantation, recovery, device longevity, and risk profile.
- Further large-scale trials are required to confirm long-term efficacy and refine patient selection for CCM therapy.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...